Asked by: Neil Coyle (Labour - Bermondsey and Old Southwark)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve specialist paediatric Pancreatic Cancer services in the NHS as part of the 10 year plan.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In England, children with cancer have their care managed by specialist paediatric cancer multi-disciplinary teams, whose responsibility it is to provide high-quality care through the effective coordination of integrated, disease specific pathways. This includes arranging for access to specialist pancreatic services, where clinically appropriate.
The 10-Year Health Plan for England includes a number of important actions that will improve children’s health and paediatric health services.
A National Cancer Plan for England will also be published this year. The plan will seek to improve every aspect of cancer care and will cover the entirety of the cancer pathway, from referral and earlier diagnosis to accessing treatment and ongoing care. It will apply to all cancer types, including pancreatic cancer, and will include a specific focus on children and young people with cancer.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people under 50 years old have been diagnosed with pancreatic cancer in the last three years.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The latest data available, from March 2025, shows that the number of people under 50 years old diagnosed with pancreatic cancer in the last three years were as follows:
Asked by: Josh Babarinde (Liberal Democrat - Eastbourne)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to improve the supply of Pancreatin for people struggling to acquire their required quantity and dosage.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department is currently managing a supply issue with the pancreatic enzyme replacement therapy (PERT) Creon, which is used by patients with conditions such as cystic fibrosis and certain cancers, including pancreatic cancer and neuroendocrine cancer. The supply issue with Creon is impacting countries throughout Europe and has been caused by the limited availability of raw ingredients and manufacturing capacity constraints to produce the volumes needed to meet demand. This is causing knock-on supply issues with alternative PERT products.
The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production. Through these discussions we have managed to secure additional volumes for 2025 for the United Kingdom.
The Department has also reached out to specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market. In May 2024, pancreatin preparations were added to the Department’s list of medicines that cannot be exported from the UK or hoarded. In the longer term, the Department has had interest from non-UK suppliers of PERT wishing to bring their products to the UK and, along with colleagues in the Medicine and Healthcare products Regulatory Agency, we are working with these potential suppliers, and if authorised, these products could further diversify and strengthen the market.
The Department has widely disseminated comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply to ensure that no patient is left without PERT.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of introducing a national screening programme for pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and which supports implementation.
The UK NSC received a submission via its 2024 annual call process to consider a new screening programme for the early detection of pancreatic cancer. The UK NSC decided to explore this proposal further, and the next step will be an evidence mapping process. Further information on the annual call process can be found at the following link:
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of trends in the level of regional variation for access to treatment for pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises that pancreatic cancer is one of the most difficult cancers to diagnose early. Its symptoms are often vague and non-specific, meaning many patients are diagnosed at a late stage, when treatment options are limited and outcomes are poor. This underlines the critical importance of improving routes to earlier diagnosis.
To address this challenge, the National Health Service has implemented non-specific symptom (NSS) pathways across England. These services support faster and more accurate diagnosis for patients who present with symptoms that do not clearly indicate a specific type of cancer, including those often seen in pancreatic cancer. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.
The NHS has launched a £2 million initiative, funding 300 general practices (GPs) to identify pancreatic cancer early by screening high-risk patients over 60 years old with new diabetes diagnoses and unexplained weight loss for urgent testing. More than 300 GPs across England will begin using the initiative, with dozens rolling it out now, and the rest to be up and running in the autumn.
Reducing inequalities and variation in cancer care, including for pancreatic cancer, is a priority for the Government. The NHS England Cancer Programme commissions clinical cancer audits, which provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatment and outcomes for patients. Rather than a single audit, NHS England commissions ten audits, by tumour type, including for pancreatic cancer. On 12 September 2024, the National Cancer Audit Collaborating Centre published its State of the Nation Report on Pancreatic Cancer, and the initial recommendations are informing improvements in treatment and care.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve early diagnosis rates for pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises that pancreatic cancer is one of the most difficult cancers to diagnose early. Its symptoms are often vague and non-specific, meaning many patients are diagnosed at a late stage, when treatment options are limited and outcomes are poor. This underlines the critical importance of improving routes to earlier diagnosis.
To address this challenge, the National Health Service has implemented non-specific symptom (NSS) pathways across England. These services support faster and more accurate diagnosis for patients who present with symptoms that do not clearly indicate a specific type of cancer, including those often seen in pancreatic cancer. There are currently 115 NSS services operating in England, ensuring more patients benefit from quicker access to the right investigations.
The NHS has launched a £2 million initiative, funding 300 general practices (GPs) to identify pancreatic cancer early by screening high-risk patients over 60 years old with new diabetes diagnoses and unexplained weight loss for urgent testing. More than 300 GPs across England will begin using the initiative, with dozens rolling it out now, and the rest to be up and running in the autumn.
Reducing inequalities and variation in cancer care, including for pancreatic cancer, is a priority for the Government. The NHS England Cancer Programme commissions clinical cancer audits, which provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments, and help stimulate improvements in cancer treatment and outcomes for patients. Rather than a single audit, NHS England commissions ten audits, by tumour type, including for pancreatic cancer. On 12 September 2024, the National Cancer Audit Collaborating Centre published its State of the Nation Report on Pancreatic Cancer, and the initial recommendations are informing improvements in treatment and care.
Asked by: Kevin Bonavia (Labour - Stevenage)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to enable earlier diagnosis for pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises that pancreatic cancer is one of the most difficult cancers to diagnose early. Its symptoms are often vague and non-specific, meaning many patients are diagnosed at a late stage when treatment options are limited and outcomes are poor. This underlines the critical importance of improving routes to earlier diagnosis.
To address this challenge, the National Health Service has implemented non-specific symptom (NSS) pathways across England. These services support faster and more accurate diagnosis for patients who present with symptoms that do not clearly indicate a specific type of cancer, including those often seen in pancreatic cancer. There are currently 115 NSS services operating, ensuring more patients benefit from quicker access to the right investigations.
The NHS has launched a £2 million initiative funding 300 general practices (GPs) to identify pancreatic cancer early by screening high-risk patients over 60 years old with new diabetes diagnoses and unexplained weight loss for urgent testing. More than 300 GPs across England will begin using the initiative, with dozens rolling it out now, and the rest to be up and running in the autumn.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many pancreatic cancer specialist nurses are employed in the NHS in England.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department does not hold information on the number of full time equivalent pancreatic cancer specialist nurses employed in the National Health Service in England.
The Nursing and Midwifery Council does not require any specific post-registration education programme to be undertaken in order for a registered nurse to become a pancreatic cancer specialist nurse. Employers develop specialist roles to meet community and service need locally.
Asked by: Carla Lockhart (Democratic Unionist Party - Upper Bann)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help support research into immunotherapy treatments for (a) pancreatic, (b) brain and (c) other difficult-to-treat cancers; and whether he plans to provide additional funding to clinical trials in this area.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests in research through its research delivery arm, the National Institute for Health and Care Research (NIHR). The NIHR continues to welcome high quality, high impact funding applications for research into any aspect of human health and care, including research into immunotherapy treatments.
The Department is committed to ensuring that all patients, including those with pancreatic, brain, and other difficult-to-treat cancers, have access to cutting-edge clinical trials and innovative, lifesaving treatments. The Department is committed to turbocharging clinical research and delivering better patient care, to make the United Kingdom a world-leading destination for clinical research. We are working to fast-track clinical trials to drive global investment into life sciences, improve health outcomes, and accelerate the development of medicines and therapies of the future, including treatments for cancer.
The Office for Life Sciences’ Cancer Healthcare Goals programme and the Medical Research Council have co-funded and awarded a £9 million grant to the MANIFEST immunotherapy platform. The MANIFEST consortium is led by the Francis Crick Institute and is composed of academia, the National Health Service, and industry partners, with the aim of expanding and advancing UK immunotherapy research and development capabilities, supporting better targeting and improved efficacy of these expensive treatments, and will look to onboard new cancer types and indications as activity progresses.
Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve awareness of symptoms of (a) lung and (b) pancreatic cancer.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to improving symptom awareness of lung cancer and pancreatic cancer, and NHS England is also taking steps to improve awareness.
NHS England runs Help Us Help You campaigns to increase knowledge of cancer symptoms and address barriers to acting on them, to encourage people to come forward as soon as possible to see their general practitioner. The campaigns focus on a range of symptoms as well as encouraging body awareness to help people spot symptoms across a wide range of cancers at an earlier point. NHS England and other National Health Service organisations, nationally and locally, also publish information on the signs and symptoms of many different types of cancer, including lung cancer and pancreatic cancer. This information can be found on the NHS website.
The Department has also committed support to the Less Survivable Cancers Taskforce, which is a group of charities focusing on cancers with poor survival rates. This partnership focuses on raising awareness of less survivable cancers, including lung cancer and pancreatic cancer, so more people understand their symptoms and go to see their general practitioner if they have concerns.
As part of developing the forthcoming National Cancer Plan for England, the Department has been working with members of the Less Survivable Cancers Taskforce to identify how to improve diagnosis, treatment, and outcomes for less survivable cancers, including lung cancer and pancreatic cancer.